COMPANY
Locus Biosciences
Timeline
- Grant Government grant: $3.3M (total, as published), announced Jan 7, 2026. Source: company's own press page. source ↗
- Partnership Partnership / licensing announced Oct 28, 2025. Source: company's own press page. source ↗
- Trial start Phase 2: A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) source ↗
- Trial start Phase 1: Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli source ↗
Upcoming milestones
- 2027-06 (ESTIMATED) · Phase 2 · A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) · NCT05488340
Funding
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05488340 | A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) | Phase 2 | Recruiting | Jul 13, 2022 | 2027-06 (estimated) |
| NCT04191148 | Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli | Phase 1 | Completed | Dec 30, 2019 | Nov 19, 2020 (actual) |
NIH awards 2
- NIH contract (government contract; not a grant and not an investment round) 75N93025C00035-P00002-9999-1 FY2026: $4,576,910 awarded for that fiscal year; activity N01 (OTHER_NIH); PI KIM, PAUL JOON; recipient as written: LOCUS BIOSCIENCES, INC., Morrisville, N source ↗
- NIH contract (government contract; not a grant and not an investment round) 75N93025C00035-0-9999-1 FY2025: $3,318,955 awarded for that fiscal year; activity N01 (OTHER_NIH); PI KIM, PAUL JOON; recipient as written: LOCUS BIOSCIENCES, INC., Morrisville, NC. De source ↗